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Background: Post-operative atrial fibrillation (pAF) following coronary artery bypass grafting 
(CABG) is a common complication. Whether pAF is associated with an increased risk of 
cerebrovascular accident (CVA) remains uncertain. We investigated the association between 
pAF and long-term risk of CVA by performing a post-hoc analysis of 10-year outcomes of the 
Arterial Revascularization Trial (ART). 
Methods: For the present analysis, among patients enrolled in the ART (n=3102), we excluded 
those who did not undergo surgery (n=25),  had a prior history of atrial fibrillation (n=45), or 
had no information regarding the incidence of pAF (n=9). The final population consisted of 
3023 patients of whom 734 (24.3%) developed pAF with the remaining 2289 maintaining sinus 
rhythm (SR). Competing risk and Cox regression analysis were used to investigate the 
association between pAF and the risk of CVA.   
Results: At 10 years, the cumulative incidence of CVA was 6.3% (4.6-8.1) vs 3.7% (2.9-4.5) 
in patients with pAF and SR respectively. pAF was an independent predictor of CVA at 10 
years (HR 1.53; 95%CI 1.06-2.23; P-value=0.025) even when CVAs that occurred during the 
index admission were excluded from the analysis (HR 1.47; 95% 1.02-2.11; P=0.04).  
Conclusions: Patients with pAF after CABG are at higher risk of CVA. These findings 





What is new? 
• Postoperative atrial fibrillation (pAF) after CABG is independently associated with a 
higher risk of cerebrovascular accidents at 10 years. 
• The association between pAF and risk of cerebrovascular accident persists  when CVAs 
that occurred before discharge are excluded. 
• pAF is also independently associated with a higher risk of cardiovascular and all-cause 
mortality. 
What are the clinical implications? 
• Our findings highlight the need to revisit the notion that pAF is a transient, benign 
condition. 
• Patients with pAF after CABG should be considered for stricter surveillance with  
continuous heart rhythm monitoring and anticoagulation therapy in those at very high 
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pAF: post-operative atrial fibrillation  
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The incidence of postoperative atrial fibrillation (pAF) following coronary artery bypass 
grafting (CABG) surgery ranges between 20% and 40%. pAF typically develops within the 
first week post-surgery, at a median time of 2 days after the operation. It generally resolves, 
with or without medication, within 24–48 hours and most patients are discharged in sinus 
rhythm (SR) [1]. While pAF has been traditionally considered a transient and benign 
complication of CABG [2], more recent studies have reported an association between pAF and 
increased early mortality and morbidity including stroke, renal and respiratory failure and a 
prolonged intensive care unit duration [3]. Although pAF may not be directly responsible for 
these poor outcomes, it is likely contributory and is, at least, a surrogate for increased morbidity 
and mortality following cardiac surgery [4,5].  
What remains unclear is whether patients who develop transient pAF are at higher risk of stroke 
after discharge as conflicting findings have been reported on the association between pAF and 
an increased risk of late stroke [6-8]. Consequently, current guidelines do not support long-
term anticoagulation in patients with pAF following CABG [9].  
The Arterial Revascularization Trial (ART) is one of the largest randomized trials of surgical 
coronary revascularization which was designed to compare 10-year outcomes after bilateral vs 
single internal thoracic artery grafts [10]. In the this post-hoc analysis, we investigated the 








A post-hoc analysis of the ART trial was conducted. For the present analysis, among patients 
enrolled in the ART (n=3102) from 2004 to 2007, we excluded those who did not undergo 
surgery (n=25),  had a prior history of atrial fibrillation/flutter before surgery (n=45), and 
those with no information regarding the incidence of pAF (n=9), as shown in Figure I in the 
Supplement.  
The remaining 3023 patients were classified based on the occurrence of pAF during their 
index admission. pAF was defined as the occurrence of any episode of atrial fibrillation or 
flutter (collectively termed pAF for this analysis) following the index procedure through the 
time of discharge that lasted at least 30 seconds and was captured on a standard 12-lead 
electrocardiogram or cardiac telemetry [11]. After discharge, all patients underwent 12-lead 
electrocardiogram within 6 weeks.  
Trial design 
The ART was approved by the institutional review board of all participating centers, and 
informed consent was obtained from each participant. The protocol of ART has been published 
[12]. Briefly, ART was a 2-arm, randomized multicenter trial conducted in 28 hospitals in 7 
countries, with patients being randomized equally to single or bilateral internal thoracic artery 
grafts. Eligible patients were those with multivessel coronary artery disease undergoing CABG 
including urgent patients. Only emergency patients (refractory myocardial 
ischemia/cardiogenic shock) and those requiring single grafts, redo CABG and concomitant 
procedures were excluded.  
Follow-up  
Questionnaires were sent to study participants by post every year after surgery. No clinic visits 
were planned apart from the routine clinical 6-week post-operative visit. Participants were sent 




ordinators contacted participants by telephone to alert them to the questionnaire’s arrival and 
to ask them about medications, adverse events and health services resource use. 
Study Endpoints 
The primary endpoint was the incidence of cerebrovascular accident (CVA) which occurred 
after discharge during the 10-year follow-up.  Secondary endpoints were 10-year 
cardiovascular (CV) and all-cause mortality.   
Endpoints definition 
CVA was defined as a new neurological deficit evidenced by clinical signs of paresis, plegia 
or new cognitive dysfunction including any mental status alteration lasting more than 24 hours 
and/or evidence on CT or MRI scan of recent brain infarct (less than 6 months). The modified 
Rankin Scale [13] was used to evaluate the degree of disability in patients who suffered a CVA. 
The scale runs from 0-6, running from perfect health without symptoms to death: 0 - No 
symptoms; 1 - No significant disability. Able to carry out all usual activities, despite some 
symptoms; 2 - Slight disability. Able to look after own affairs without assistance, but unable to 
carry out all previous activities; 3 - Moderate disability. Requires some help, but able to walk 
unassisted; 4 - Moderately severe disability. Unable to attend to own bodily needs without 
assistance, and unable to walk unassisted; 5 - Severe disability. Requires constant nursing care 
and attention, bedridden, incontinent; 6 - Dead. 
Death was classified as cardiovascular and non-cardiovascular, using autopsy reports and death 
certificates. Cardiovascular deaths were defined as deaths due to cardiac causes (i.e. congestive 
heart failure, arrhythmias, myocardial infarction) and vascular causes (i.e. CVA, dissection and 
pulmonary embolism).   
Major bleeding was defined according to the Bleeding Academic Research Consortium 




patient hemodynamically (3b), requiring surgical reintervention (type 4) or resulting in patient 
death (type 5) [14]. 
Statistical analysis  
A set of baseline characteristics were selected to adjust the association between pAF and the 
risk of CVA: age, female sex, New York Heart Association (NYHA) class, left ventricular 
ejection fraction (LVEF), diabetes, smoking status, chronic obstructive pulmonary disease 
(COPD), arterial hypertension (medically treated), prior myocardial infarction (MI), body mass 
index (BMI), creatinine, previous CVA, peripheral vascular disease, unstable angina, previous 
percutaneous coronary intervention (PCI), off-pump surgery and total number of grafts.  The 
rate of missing data for these variables was low (Figure II in the Supplement) and missing data 
were handled with multiple imputation (i.e. 10 imputed datasets) with multivariate imputation 
by chained equations (MICE). Individual coefficients from each imputed dataset were 
combined based upon Rubin’s rules for pooling [15]. For the comparison of baseline 
characteristics between patients with stable sinus rhythm (SR group) and with pAF (pAF 
group), categorical variables were compared between the two groups with the chi-square test 
or Fisher’s exact test for categorial variables and Student’s t-test or the Wilcoxon rank-sum test 
for non-normally distributed continuous variables. The 10-year cumulative incidence of CVA 
and CV mortality in the two groups was calculated using competing risk analysis for CVA and 
CV mortality, accounting for the competing risk of death, as proposed by Fine and Gray [16]. 
The cumulative incidence for all-cause mortality was calculated using 1-Kaplan–Meier 
estimates. The association between pAF and primary and secondary endpoints was estimated 
as a sub-distribution hazard ratio (HR) and its 95% confidence interval derived from 
univariable and bi-directional stepwise multivariable Cox models. Variables included in the 




Proportional hazard assumption was assessed with Schoenfeld residuals and global p was 
reported. The SR group was used as the reference group in all analyses. Adjusted P for multiple 
comparisons (primary and secondary endpoints) was calculated using Bonferroni-Holm 
correction. 
For sensitivity analysis, the association between pAF and the primary outcomes was 
recalculated restricting the analysis only to CVA that occurred after discharge or excluding 
patients with evidence of pAF within 6 weeks following discharge. Finally, we calculated the 
CHA2DS2VASc for each patient, which is a widely adopted tool to stratify patients based on 
their predicted risk of CVA [17]. To investigate if pAF was associated with an additional risk 
across CHA2DS2VASc score categories, the interaction between CHA2DS2VASc and pAF on 
the risk of CVA was explored by forcing their interaction term in a Cox regression model. 
Relative Hazard was calculated and plotted for each CHA2DS2VASc categories in the pAF and 
SR groups. We then defined high risk patients as those with CHA2DS2VASc ≥4 which 
corresponds to the 75th percentile of its distribution. The cumulative incidence of CVA is 
reported in 4 groups stratified by rhythm status (pAF vs SR) and baseline CHA2DS2VASc (<4 
vs ≥4). The relative risk of CVA was calculated across the groups as Hazard ratio and 95%CI 
using univariable Cox regression and using patients with SR and CHA2DS2VASc score<4 for 
reference. As only a small number of patients in the pAF group received vitamin K antagonists 
(i.e. Warfarin), we reported the cumulative incidence of major bleeding and CVA stratified for 
anticoagulation therapy received for descriptive purpose only. P values <0.05 were considered 
significant. Statistical analyses were performed using R Statistical Software (version 3.2.3; R 
Foundation for Statistical Computing, Vienna, Austria) and the following packages: mice for 
multiple imputation, survival for survival analysis, finalfit for univariate and multivariate 





Study population  
The final population consisted of 3023 patients. Of whom, 734 (24.3%) and 2289 (75.7%) 
patients presented with pAF or stable SR respectively during the index hospitalization. Baseline 
characteristics in the two groups are presented in Table 1.  The incidence of CVA during index 
admission was 14 (1.9%) and 23 (1.0%) in the pAF and SR groups, respectively. Hospital 
mortality was 13 (1.8%) and 16 (0.7%) in the pAF and SR groups, respectively. In 676 (92.1%) 
patients in the pAF group, stable SR was restored before discharge. In the SR group, 20 patients 
presented with new onset of AF within 6 weeks after discharge. 
Medications at discharge in the two groups are presented in Table I in the Supplement. In the 
pAF group, Warfarin was prescribed in 61 (8.3%) patients (12 with persistent pAF and the 
remaining 49 with SR restoration), while in the SR group, Warfarin was prescribed in 18 
(0.8%) patients. As expected, the proportion of patients discharged on amiodarone was higher 
in the pAF group (47.7% vs 1.7%).   
Association between pAF and 10-year outcomes 
During 10-year follow-up, a total of 46 (6.3%) CVA were recorded (23 ischemic, 4 
haemorrhagic and 19 unknown aetiology) in the pAF group. Their median modified Rankin 
score was 3.0 [interquartile range 1-5]. A total of 83 (3.6%) CVA were recorded in the SR 
group (55 ischemic, 7 haemorrhagic and 21 unknown aetiology). Their median modified 
Rankin score was 2.5 [interquartile range 1-4] (Table II in the Supplement).  The cumulative 
incidence of CVA at 10 years was 6.3% (4.6-8.1) vs 3.7% (2.9-4.5) in the pAF and SR groups 
respectively (Table III in the Supplement). With univariable and multivariable Cox regression 
(Table 2), pAF was found to be an independent predictor of CVA at 10 years (HR 1.53; 95%CI 




Causes of death are reported in Table IV in the Supplement. CVA was reported as cause of 
death in 21 (9.7%) out of 216 total deaths and in 15 (3.8%) out of 394 total deaths in the pAF 
and SR groups, respectively. At 10 years the cumulative incidence of cardiovascular and all-
cause mortality was 11.1% (8.8-13.4) vs 6.4% (5.3-7.4) and 30.2% (26.8-33.6) vs 18% (16.4-
19.6) in the pAF and SR groups, respectively. pAF was independently associated with 
increased risk of cardiovascular mortality (HR 1.48; 95%CI 1.11-1.97; Bonferroni-Holm 
corrected P-value=0.01; Global P=0.60; Table 3, Figure 2 Panel A) and all-cause mortality (HR 
1.34; 95%CI 1.13-1.59; Bonferroni-Holm corrected P-value=0.03; Global P=0.10; Table V in 
the Supplement;  Figure 2 Panel B). Sensitivity analysis confirmed that an independent 
association between pAF and risk of CVA at 10 years also existed when CVA that occurred 
during the index admission was excluded (HR 1.47; 95% 1.02-2.11; P=0.04; Table VI in the 
Supplement; Figure 1 Panel B) and when patients with evidence of atrial fibrillation within 6 
weeks from discharge were excluded (HR 1.49; 95%CI 1.04-2.16; P=0.032; Table VII in the 
Supplement ).   In the pAF group, the cumulative incidence of CVA and major bleeding at 10 
years was 3.6%(0-8.4%) vs 5.3%(3.5-7.0) (Table VIII in the Supplement) and 3.4%(0.0-8.1) 
vs 4.1%(2.6-5.7) (Table IX in the Supplement) in patients discharged with and without 
Warfarin.  
Prognostic implication of CHA2DS2-VASc score in patients with pAF 
The distribution of baseline CHA2DS2-VASc score in the pAF and SR groups is reported in 
Table X in the Supplement. Mean CHA2DS2-VASc score was 3.46±1.31 vs 3.17±1.29 in the 
pAF and SR groups respectively (P<0.001). We found a significant interaction between 
CHA2DS2-VASc and pAF on the risk of CVA (p=0.01; Figure III in the Supplement). The 
cumulative incidence of CVA in the pAF and SR groups stratified by CHA2DS2-VASc score 
is reported in Table XI in the Supplement. The risk of CVA was comparable between pAF and 




CHA2DS2-VASc score ≥4. Compared to patients with CHA2DS2-VASc score <4 in the SR 
group, patients with CHA2DS2-VASc score ≥4 and SR were associated with 2-fold relative risk 
increase of CVA (HR 2.13[95%CI 1.38-3.27]) whilst those with CHA2DS2-VASc score ≥4 and 
pAF were associated with 4-fold relative risk increase of CVA (HR 4.05[95%CI 2.54-
6.46])(Figure 3).  
Results regarding the prognostic implication of CHADS2 score [18], an earlier and simplified 
form of CHA2DS2-VASc score are presented in Supplemental material (Tables XII and XIII in 
the Supplement; Figure IV in the Supplement). 
Discussion  
In the cohort of patients undergoing CABG surgery in the ART trial, we found a significant 
association between pAF and the risk of CVA at 10 years and this association continued after 
controlling for potential confounders.  Half the patients developing CVA, presented with the 
least moderate disability (i.e. median Rankin = 3).  In patients with pAF, CVA was more 
frequently reported as the cause of death compared to patients who remained in SR. Overall, 
pAF was associated with an increased risk of cardiovascular and all-cause mortality.  
pAF has long been considered a benign, self-limiting condition which converts to SR before 
hospital discharge in most cases [2]. However, recent evidence suggested that the occurrence of pAF is 
associated with patients with larger burden of comorbidities, so that causality between pAF and 
long-term mortality remains unclear [4,5].   
Limited and conflicting data are available on the association between pAF and CVA. To the 
best of our knowledge, no previous study has demonstrated the association between pAF and 
long-term (>10 years) risk of CVA. By using linked administrative data in the province of 
Ontario between 1996 and 2006, Whitlock et al. reported that pAF was associated with an 




the Excel trial reported an increased risk of stroke at 3 years following CABG in patients with 
pAF.[7] In both studies, the association between pAF and the risk of stroke was mainly driven 
by events occurring before discharge, In contrast, a recent analysis from the Danish nationwide 
registries showed no significant increase in the risk of thromboembolism in patients with pAF 
after CABG. However, AF was associated with an increased risk of rehospitalization for atrial 
fibrillation [8].   
In the present analysis we found an independent association between pAF and 10-year risk of 
CVA. Although a relevant number of CVA occurred within 30 days, the incidence of CVA 
continued to be higher in the pAF patients at mid- and long-term follow-up and the association 
between pAF and CVA persisted when CVA that occurred during index hospitalization was 
excluded. The association of pAF with CVA was evident even in patients with high CHA2DS2-
VASc score (≥4). If this association is validated in other studies, this finding could be used to 
stratify patients with pAF and identify those who may benefit from stricter surveillance with 
continuous heart rhythm monitoring or anticoagulation therapy. In particular, little evidence 
exists on the efficacy and safety of anticoagulation therapy in patients with pAF and current 
recommendations are mainly driven by the therapy for non-surgical AF modified by the 
potential risk of bleeding in the postoperative period [19]. Current guidelines recommend 
anticoagulation for patients with a prolonged duration of pAF (>48 hours) [20] for at least 4 
weeks. However, it remains unclear if the benefit of long-term anticoagulation for 
thromboembolism prevention outweighs the bleeding risk in this population. It must also be 
considered that post-CABG patients usually  receive one or two antiplatelet agents to prevent 
graft failure, and the combination of antiplatelet and anticoagulation therapies might 
significantly increase the risk of bleeding.  The present post-hoc analysis was largely 
underpowered to investigate whether the prescription of anticoagulation therapy was associated 




cumulative incidence of CVA in the pAF group was lower among patients discharged on 
Warfarin and that patients discharged on Warfarin presented a comparable risk of severe 
bleeding when compared to patients discharged without it. Further benefit may be achieved by 
the use of novel oral anticoagulants (NOAC), which can prevent new CVA in high risk patients 
with a reduced risk of bleeding compared to Warfarin. This is related to a safer 
pharmacodynamic profile and fewer interactions with other drugs and food, which prevent 
supratherapeutic INR, traditionally associated with Warfarin. In a retrospective analysis of 960 
patients undergoing isolated CABG, 29 patients with pAF were discharged on NOAC 
compared to 77 discharged on Warfarin. Late post-operative outcomes showed three 
readmissions for major bleeding, all in patients discharged on Warfarin, while no readmissions 
for major bleeding were recorded in patients discharged on a novel anticoagulation regimen 
[21].  
Moreover, attention to each episode of pAF, regardless of its duration, should be raised in order 
to tailor a stricter surveillance in patients developing this complication. In fact, pAF has been 
shown to be associated with the late recurrence of atrial fibrillation, which exposes the patients 
to the risk of CVA and late mortality [22-23]. Hence, this requires the clinician to undertake a 
more intense follow-up with the aim of identifying late recurrence of arrhythmias in a timely 
manner.  
The present analysis has several limitations. We had no information on the duration of pAF in 
those cases with sinus rhythm restoration before discharge and therefore we were unable to 
correlate the duration of pAF with clinical outcomes. Moreover, the ART cohort enrolled a 
relatively low-risk subset of CABG patients and these results may not be generalizable to the 
real-world CABG population. The ART trial used questionnaires for follow-up, and it is 
possible that adverse events may have been underreported. However, for patients requiring 




were collected.  As previously highlighted, this post-hoc analysis was largely underpowered to 
detect any difference in clinical outcomes in patients discharged on anticoagulation therapy 
and larger studies are needed to define risks and benefits of such therapy in patients with pAF. 
Finally, studies using continuous heart rhythm monitoring are needed to assess the risk of 
recurrence of atrial dysrhythmias in patients with pAF. 
In conclusion, in the ART trial the occurrence of pAF following CABG was associated with 
an increased 10-year risk of CVA and mortality. This association highlights the need to revisit 
the notion that pAF is a transient, benign condition. In particular, special consideration should 
be given to patients at higher baseline risk of CVA (CHA2DS2-VASc≥4) who develop pAF.  
 
Founding: The Arterial Revascularization Trial was supported by grants from the British Heart 
Foundation (SP/03/001), the U.K. Medical Research Council (G0200390), and the National 
Institute of Health Research Efficacy and Mechanism Evaluation Programme (09/800/29). 
Umberto Benedetto contribution was supported by the National Institute of Health Research 
Bristol Biomedical Research Centre. Alastair Gray is partly supported by the National Institute 
of Health Research Oxford Biomedical Research Centre. 






List of the investigators in the Arterial Revascularization Trial 
Expanded results 
Supplemental Tables I – XIII 






1. Mathew, J. P., Fontes, M. L., Tudor, I. C., Ramsay, J., Duke, P., Mazer, C. D., Barash, 
P. G., Hsu, P. H., Mangano, D. T. Investigators of the Ischemia Research and Education 
Foundation; Multicenter Study of Perioperative Ischemia Research Group. A 
multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004; 
291:1720-1729 
2. Greenberg JW, Lancaster TS, Schuessler RB, Melby SJ. Postoperative atrial fibrillation 
following cardiac surgery: a persistent complication. Eur J Cardiothorac Surg. 2017; 
52:665-672. 
3. Saxena A, Dinh DT, Smith JA, Shardey GC, Reid CM, Newcomb AE. Usefulness of 
postoperative atrial fibrillation as an independent predictor for worse early and late 
outcomes after isolated coronary artery bypass grafting (multicenter Australian study 
of 19,497 patients). Am J Cardiol. 2012;109:219-225.  
4. El-Chami, M. F., Kilgo, P., Thourani, V., Lattouf, O. M., Delurgio, D. B., Guyton, R. 
A., Leon, A. R., Puskas, J. D. New-onset atrial fibrillation predicts long-term mortality 
after coronary artery bypass graft. J Am Coll Cardiol. 2010;55:1370-1376. 
5. Mariscalco, G., Klersy, C., Zanobini, M., Banach, M., Ferrarese, S., Borsani, P., 
Cantore, C., Biglioli, P., Sala, A. Atrial fibrillation after isolated coronary surgery 
affects late survival. Circulation. 2008;118:1612-1618 
6. Whitlock R, Healey JS, Connolly SJ, Wang J, Danter MR, Tu JV, Novick R, Fremes 
S, Teoh K, Khera V, et al. Predictors of early and late stroke following cardiac surgery. 
CMAJ. 2014;186:905-911. 
7. Kosmidou I, Chen S, Kappetein AP, Serruys PW, Gersh BJ, Puskas JD, Kandzari DE, 




or CABG for Left Main Disease: The EXCEL Trial. J Am Coll Cardiol. 2018;71:739-
748 
8. Butt JH, Xian Y, Peterson ED, Olsen PS, Rørth R, Gundlund A, Olesen JB, Gislason 
GH, Torp-Pedersen C, Køber L, et al. Long-term Thromboembolic Risk in Patients 
With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and 
Patients With Nonvalvular Atrial Fibrillation. JAMA Cardiol. 2018;3:417-424. 
9. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, 
Ellinor PT, Ezekowitz MD, Field ME, et al. 2014 AHA/ACC/HRS guideline for the 
management of patients with atrial fibrillation: executive summary: a report of the 
American College of Cardiology/American Heart Association Task Force on Practice 
Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:2246-2280. 
10. Taggart DP, Altman DG, Gray AM, Lees B, Gerry S, Benedetto U, Flather M. ART 
Investigators. Randomized Trial of Bilateral versus Single Internal-Thoracic-Artery 
Grafts. N Engl J Med. 2016;375:2540-2549. 
11. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano 
RJ Jr, Davies DW, DiMarco J, et al. 2012 HRS/EHRA/ECAS Expert Consensus 
Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations 
for patient selection, procedural techniques, patient management and follow-up, 
definitions, endpoints, and research trial design. Europace. 2012;14:528-606. 
12. Taggart DP, Lees B, Gray A, Altman DG, Flather M, Channon K; ART Investigators 
Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to compare 
survival following bilateral versus single internal mammary grafting in coronary 




13. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic 
attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 
1991;54:1044–1054. 
14. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott 
SD, Menon V, Nikolsky E, et al. Standardized bleeding definitions for cardiovascular 
clinical trials: A consensus report from the Bleeding Academic Research Consortium. 
Circulation. 2011;123:2736-2747. 
15. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley 
and Sons; 2004. 
16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing 
risk. JASA. 1999;94:496–509. 
17. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk 
stratification for predicting stroke and thromboembolism in atrial fibrillation using a 
novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 
2010;137:263-272.  
18. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P. 
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in 
patients taking aspirin. Circulation. 2004;110:2287-2292. 
19. Epstein AE, Alexander JC, Gutterman DD, Maisel W, Wharton JM. Anticoagulation: 
American College of Chest Physicians guidelines for the prevention and management 
of postoperative atrial fibrillation after cardiac surgery. Chest 2005; 128:24S-27S. 
20. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, 
Ellinor PT, Ezekowitz MD, Field ME, et al. 2014 AHA/ACC/HRS guideline for the 




American College of Cardiology/American Heart Association Task Force on practice 
guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071-2104. 
21. Woldendorp K, Khadra S, Bannon P, Robinson B. Novel Oral Anticoagulants 
Compared to Warfarin for Postoperative Atrial Fibrillation After Isolated Coronary 
Artery Bypass Grafting. Hear Lung Circ. In press. DOI: 10.1016/j.hlc.2020.04.018.  
22. Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrillation in patients 
undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial 
fibrillation and a doubled cardiovascular mortality. Eur J Cardiothorac Surg. 
2010;37:1353-1359. 
23. Antonelli, D., Peres, D., Freedberg, N.A., Feldman, A. And Rosenfeld, T. Incidence of 
Postdischarge Symptomatic Paroxysmal Atrial Fibrillation in Patients Who Underwent 







Figure 1. Cumulative incidence of cerebrovascular accident (CVA) in patients with 
postoperative atrial fibrillation (pAF) and stable sinus rhythm (SR) (Panel A) in the overall 
sample. Cumulative incidence of CVA in patients with pAF and stable SR after discharge (i.e. 
CVA that occurred during index hospitalization were excluded) (Panel B).  
Figure 2. Cumulative incidence of cardiovascular (CV) deaths in patients with postoperative 
atrial fibrillation (pAF) and stable sinus rhythm (SR) (Panel A). Cumulative incidence of all-
cause deaths in patients with pAF and stable SR (Panel B).  
Figure 3. Cumulative incidence of cerebrovascular accident (CVA) with postoperative atrial 





Table 1. Baseline characteristics in patients with and without postoperative atrial fibrillation  
 pAF SR   p 
n    734    2289   
Age, year (mean (SD))  66.41 (8.16)   62.58 (8.93)   <0.001  
Ethnicity, n (%)           <0.001  
Caucasian    710 (96.7)     2064 (90.2)      
East Asian      1 (0.1)        5 (0.2)      
South Asian     19 (2.6)      129 (5.6)      
Afro-Caribbean      0 (0.0)        2 (0.1)      
African      0 (0.0)        5 (0.2)      
Hispanic      4 (0.5)       84 (3.7)      
Female, n (%)     99 (13.5)      331 (14.5)     0.55 
LVEF, n (%)            0.035  
≥ 50%    527 (71.8)     1743 (76.1)      
30-50%     186 (25.3)      503 (22.0)      
< 30%      21 (2.9)       43 (1.9)      
Peripheral Vascular Disease, n (%)     55 (7.5)      154 (6.7)     0.53 
Creatinine, mmol/l (mean (SD))   98.63 (23.72)   95.90 (21.07)    0.003  
Body Mass Index, (mean (SD ))  28.29 (3.88)   28.18 (4.08)    0.51 
COPD, n (%)     18 (2.5)       55 (2.4)     1.000  
Smoking, n (%)            0.07 
Current     90 (12.3)      346 (15.1)      
Ex-smoker    435 (59.3)     1258 (55.0)      
Never smoked    209 (28.5)      685 (29.9)      
Previous cerebrovascular accident, n (%)     48 (6.5)      129 (5.6)     0.41 
NYHA class 3 or 4, n (%)    134 (18.3)      509 (22.2)     0.025  
Diabetes, n (%)            0.17 
No    546 (74.4)     1771 (77.4)      
Insulin-dependent     49 (6.7)      119 (5.2)      
Non-insulin dependent    139 (18.9)      399 (17.4)      
Arterial hypertension, n (%)    579 (78.9)     1766 (77.2)     0.35 
Unstable angina, n (%)     53 (7.2)      182 (8.0)     0.57 
Prior MI, n (%)    326 (44.4)      938 (41.0)     0.11 
Prior PCI, n (%)    124 (16.9)      354 (15.5)     0.39 
Off-pump surgery, n (%)    268 (36.5)      969 (42.3)     0.006  
Number of grafts, mean (SD)   3.23 (0.81)    3.17 (0.81)    0.06 
pAF: post-operative atrial fibrillation; SR: sinus rhythm; LVEF: left ventricular ejection 
fraction; COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular accident: 
NYHA: New York Heart Association; MI: myocardial infarction; PCI: percutaneous 




Table 2. Association between clinical variables and cerebrovascular accidents at 10 years.  
Variables             HR 95% CI  
(univariable) 
HR 95% CI 
 (multivariable) 
pAF (SR as reference)                                             1.79 (1.25-2.57, p=0.001)  1.53 (1.06-2.23, p=0.025) 
Age                                                   
 
 1.07 (1.05-1.10, p<0.001)  1.07 (1.05-1.10, p<0.001) 
Ethnicity                                        Caucasian      Reference Reference 
                                                      East-Asian     0.00 (0.00-Inf, p=0.995)   0.00 (0.00-Inf, p=0.996) 
                                                      South-Asian        0.46 (0.15-1.45, p=0.186)  0.89 (0.28-2.87, p=0.847) 
                                                      Afro-Caribbean   0.00 (0.00-Inf, p=0.997)   0.00 (0.00-Inf, p=0.998) 
                                                      African   0.00 (0.00-Inf, p=0.996)   0.00 (0.00-Inf, p=0.996) 
                                                      Hispanic  2.88 (1.51-5.49, p=0.001)  4.95 (2.48-9.90, p<0.001) 
Female gender                           1.99 (1.33-2.97, p=0.001)  1.62 (1.07-2.46, p=0.024) 
LVEF                                 ≥ 50% Reference 
 
                                                      30-50 %        1.38 (0.94-2.03, p=0.101)                          - 
                                                      < 30%        1.36 (0.43-4.29, p=0.603)                          - 
Peripheral Vascular Disease                          1.05 (0.53-2.06, p=0.892)                          - 
Creatinine                                             1.01 (1.00-1.01, p=0.026)                          - 
Body Mass Index                                         0.99 (0.95-1.04, p=0.709)                          - 
COPD                                             1.74 (0.71-4.26, p=0.224)                          - 
Smoking                                               Current      Reference 
 
                                                      Ex-smoker  0.77 (0.47-1.27, p=0.311)  0.52 (0.31-0.87, p=0.013) 
                                                      Never smoked      1.05 (0.62-1.77, p=0.857)  0.60 (0.35-1.05, p=0.072) 
Prior CVA                                         3.26 (2.02-5.25, p<0.001)  2.56 (1.58-4.15, p<0.001) 
NYHA class 3 or 4                                        
 
 0.73 (0.46-1.16, p=0.184)  0.61 (0.37-0.98, p=0.043) 
Diabetes                                              No Reference 
 
                                                      Insulin-dependent  1.07 (0.50-2.30, p=0.869)                          - 
                                                      Non-insulin 
dependent 
 1.12 (0.72-1.74, p=0.602)                          - 
Arterial hypertension                              
 
 1.59 (0.98-2.55, p=0.058)                          - 
Unstable angina                                  
 
 0.79 (0.39-1.61, p=0.514)                          - 
Prior MI                                               
 
 1.06 (0.75-1.50, p=0.740)                          - 
Prior PCI  
 
 1.57 (1.04-2.37, p=0.033)  1.85 (1.22-2.80, p=0.004) 
Off-pump surgery                                             
 
 1.27 (0.90-1.80, p=0.173)                          - 
Number of grafts                                     
 
 1.04 (0.84-1.28, p=0.737)                          - 
pAF: post-operative atrial fibrillation; SR: sinus rhythm; LVEF: left ventricular ejection 
fraction; COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular accident: 
NYHA: New York Heart Association; MI: myocardial infarction; PCI: percutaneous 




Table 3. Association between clinical variables and cardiovascular mortality at 10 years. 
pAF: post-operative atrial fibrillation; SR: sinus rhythm; LVEF: left ventricular ejection 
fraction; COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular accident: 
NYHA: New York Heart Association; MI: myocardial infarction; PCI: percutaneous 
coronary intervention 
Variables             HR 95% CI 
(univariable) 
HR 95% CI (multivariable) 
pAF (SR as reference)                                                   1.86 (1.42-2.45, p<0.001)   1.48 (1.11-1.97, p=0.007) 
Age                                                   
 
  1.08 (1.06-1.10, p<0.001)   1.08 (1.06-1.10, p<0.001) 
Ethnicity                                        Caucasian      Reference  
                                                      East-Asian    2.19 (0.31-15.65, p=0.433)  7.77 (1.07-56.53, p=0.043) 
                                                      South-Asian         0.53 (0.23-1.19, p=0.123)   1.11 (0.49-2.56, p=0.798) 
                                                      Afro-Caribbean    0.00 (0.00-Inf, p=0.991)    0.00 (0.00-Inf, p=0.994) 
                                                      African  3.49 (0.49-24.90, p=0.212)  4.48 (0.59-34.16, p=0.148) 
                                                      Hispanic   1.88 (1.05-3.37, p=0.033)   2.99 (1.61-5.57, p=0.001) 
Female gender                          2.18 (1.61-2.95, p<0.001)   2.13 (1.54-2.94, p<0.001) 
LVEF                                 ≥ 50% Reference  
                                                      30-50 %         2.38 (1.80-3.15, p<0.001)   2.18 (1.63-2.92, p<0.001) 
                                                      < 30%        5.35 (3.13-9.15, p<0.001)   3.96 (2.27-6.90, p<0.001) 
Peripheral Vascular 
Disease                         
      1.91 (1.27-2.87, p=0.002)                           - 
Creatinine                                            
 
  1.01 (1.01-1.02, p<0.001)   1.01 (1.00-1.01, p<0.001) 
Body Mass Index                                       
 
  1.01 (0.98-1.05, p=0.378)                           - 
COPD                                              1.88 (0.97-3.67, p=0.063)                           - 
Smoking                                               Current Reference  
                                                      Ex-smoker   0.70 (0.49-1.00, p=0.051)   0.43 (0.30-0.63, p<0.001) 
                                                      Never smoked       0.65 (0.44-0.97, p=0.034)   0.35 (0.23-0.53, p<0.001) 
Prior CVA                                          2.35 (1.56-3.54, p<0.001)   1.70 (1.12-2.59, p=0.012) 
NYHA class 3 or 4                                        
 
  1.48 (1.10-1.99, p=0.009)                           - 
Diabetes                                              No Reference  
                                                      Insulin-
dependent 
  2.70 (1.79-4.07, p<0.001)   1.86 (1.22-2.85, p=0.004) 
                                                      Non-insulin 
dependent 
  1.21 (0.86-1.71, p=0.265)   1.11 (0.78-1.57, p=0.567) 
Arterial hypertension                              
 
  1.49 (1.04-2.13, p=0.028)                           - 
Unstable angina                                  
 
  1.39 (0.90-2.14, p=0.137)                           - 
Prior MI                                               
 
  1.76 (1.35-2.30, p<0.001)   1.47 (1.11-1.94, p=0.007) 
Prior PCI  
 
  1.05 (0.73-1.50, p=0.792)                           - 
Off-pump surgery                                             
 
1.38 (1.06-1.79, p=0.017)                           - 
Number of grafts                                     
 
  0.95 (0.81-1.12, p=0.561)                           - 
